Shanghai Pharmaceuticals' SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment
CompanyDrug

Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment

Sperogenix Therapeutics' Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment
CompanyDrug

Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy
Policy / Regulatory

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials

Merck's PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China
CompanyDrug

Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China

MSD's Noxafil Receives NMPA Approval for Pediatric Use in Antifungal Treatment
CompanyDrug

MSD’s Noxafil Receives NMPA Approval for Pediatric Use in Antifungal Treatment

NMPA Approves Zynlonta for Relapsed or Refractory Large B-Cell Lymphoma Treatment
CompanyDrug

NMPA Approves Zynlonta for Relapsed or Refractory Large B-Cell Lymphoma Treatment

Wuhan YZY Biopharma's M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
CompanyDrug

Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024

Porton Pharma Solutions and OD Kingsley Life Sciences Form Partnership for Bio Conjugated Drug Development
CompanyDeals

Porton Pharma Solutions and OD Kingsley Life Sciences Form Partnership for Bio Conjugated Drug Development

Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter
CompanyMedical Device

Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter

Immunofoco's IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer
CompanyDrug

Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer

InnoVec Biotherapeutics' IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment
CompanyDrug

InnoVec Biotherapeutics’ IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment